Aviragen Therapeutics (AVIR) Tops Q2 EPS by 15c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.41), $0.15 better than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• 'No panic anywhere' may be the problem, BofA strategists warn
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says